RecruitingNCT06322667
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Sponsor
Eisai Co., Ltd.
Enrollment
5,000 participants
Start Date
Feb 14, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- All participants who are treated with lecanemab in routine clinical practice
Exclusion Criteria1
- None
Interventions
OTHERNo Intervention
This is a non-interventional study.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06322667
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Lombard Cohort of Brain Health Services
NCT074571385 locations
Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.
NCT074674601 location
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT072349422 locations
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216111 locations